Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report by Bonfante, G. et al.
Urology Case Reports 34 (2021) 101444
Available online 9 October 2020
2214-4420/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Oncology 
Exceptional response to immunotherapy in association with radiotherapy in 
patient with breast metastasis from urothelial carcinoma: A case report 
Giulia Bonfante a,*, Emanuela Fantinel b, Cristina Masini b, Franco Bergamaschi c, 
Salvatore Micali a, Bernardo Rocco a 
a Department of Urology, University of Modena and Reggio Emilia, 41124 Modena, Italy 
b Department of Medical Oncology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy 
c Department of Urology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy   
A R T I C L E  I N F O   
Keywords: 
Metastatic urothelial carcinoma 
Breast metastasis 
Immune checkpoint inhibitor 
PD-1 
Radiotherapy 
A B S T R A C T   
Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pem-
brolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), rep-
resents an effective second-line therapy for advanced UC. Radiotherapy has been shown to induce a mechanism 
of immunogenic cell death (ICD) resulting in immune memory and advantageous systemic effects. We present the 
first case of breast metastasis (BM) from a UC described in literature who had an exceptional response to second- 
line therapy with pembrolizumab in association with radiotherapy, showing the efficacy of combining immu-
notherapy and radiotherapy even in patients with atypical metastatic sites.   
Introduction 
UC is one of the most widespread cancers worldwide, with around 
430,000 new diagnoses each year. Most patients have a superficial non- 
muscle invasive disease, whereas about 30%–40% presents at diagnosis 
or develops muscle-invasive and/or metastatic disease, and atypical 
sites of metastasis are rare.1 
Although platinum-based chemotherapy remains the standard first- 
line treatment for patients with metastatic UC rarely achieve complete 
and durable response, with a 5-year overall survival (OS) rate of 15% 
and after failure, there were few data available for the choice of second- 
line treatment.2 
New knowledge about mechanism of UC progression and involve-
ment of immune system led to development of immune checkpoint in-
hibitors (ICIs) targeting either PD-1 or PD-L1 that have shown efficacy in 
different settings of UC. In phase III trial KEYNOTE-045, pembrolizumab 
improved OS compared with control arm in patients with metastatic UC 
progressed during or after platinum-based chemotherapy, regardless of 
PD-L1 tumour expression status and with good tolerability.3 
Case presentation 
In this reported case, a 61-year-old woman presented to emergency 
room due to new-onset macrohematuria and irritative voiding symp-
toms. An abdomen ultrasound (US) showed a vascularized mass (Ø 70 ×
70 mm) in basal right-side wall of bladder and initial right hydro-
nephrosis. The patient was hospitalized and received blood transfusions 
for anaemia caused by haematuria (Hb 4.8 gr/dl). Blood tests also re-
ported an increase in creatinine basal level from 1.37 to 1.8 mg/dl. 
Abdomen and chest CT scan confirmed the presence of intraluminal 
mass (Ø 70 × 60 mm) involving right half of the bladder and showed a 
lymphadenopathy (Ø 31 × 26 mm) in right iliac region. Other lymph 
nodes appeared bilateral along external iliac vessels, the largest on left 
side (maximum short axis 13 mm). There was no evidence of metastatic 
disease at baseline CT scan and bone scintigraphy. 
Pathological investigation of specimens obtained by transurethral 
resection of bladder tumour (TURBT) showed a high-grade urothelial 
papillary carcinoma with invasion of lamina propria (pT1 WHO 2016). 
The absence of detrusor muscle in the sample probably underestimated 
the disease. To have an accurate staging and to stop bleeding, a salvage 
radical cystectomy with an extended lymphadenectomy and an ureter-
ocutaneostomy was performed. Post-surgical staging was pT3b N1 M0 
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(sec WHO 2016). 
During post-operative hospitalization, patient found a right breast 
nodule through breast self-examination, confirmed by mammography 
and US (Ø 25 × 35 mm). The histological and immunohistochemistry 
(estrogenic receptor negative, CK20 positive, p63 positive) examination 
of needle biopsy was diagnostic for a metastatic localization from UC 
(Fig. 1). 
The CT scan performed after surgery revealed the presence of a 
subcutaneous nodule on the left side of thorax wall (Ø 13 × 18 mm) and 
a lymphadenopathy (short axis <15 mm) near external left iliac artery. 
Given the evidence of metastatic disease, patient underwent a first- 
line chemotherapy regimen with carboplatin and gemcitabine. After 3 
cycles radiological assessment showed a partial response of breast 
metastasis (reduced to Ø 32 × 28 mm) according to RECIST v 1.1 
criteria. After 6 cycles of chemotherapy, imaging showed disease pro-
gression. Target breast lesion increased to Ø 35 × 35 mm and CT scan 
revealed numerical and dimensional increase of lymph nodes in para- 
aortic region. 
We performed a genomic analysis supported by FoundationO-
ne®CDx on tissue samples obtained by breast biopsy, which identified 
alterations in genes BCL2L1, CDKN2A, MYC, RAF1, TP53 known to be 
cancer related. No actionable mutations were identified. Immunohisto-
chemical test of PD-L1 was then performed with IHC 22C3 antibody 
(Dako North America) and evaluated with Combined Positive Score 
(CPS = percentage of PD-L1 expressing tumour and infiltrating immune 
cells relative to total number of tumour cells).3 PD-L1 expression was 
30% (Fig. 2). 
Considering disease progression and results of genetic and immu-
nohistochemical analyses, patient underwent a second-line treatment 
Fig. 1. Immunohistochemistry of breast metastasis. A) negative value for estrogenic receptor (ER); B) positive value in brown for CK20; C) positive value in brown 
for p63. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
Fig. 2. Immunohistochemistry of breast metastasis. PD-L1 CPS 30%: tumour 
cells and infiltrating immune cells expressing PD-L1 in brown. (For interpre-
tation of the references to colour in this figure legend, the reader is referred to 
the Web version of this article.) 
Fig. 3. Computed Tomography (CT) Images of the breast metastatis. A) CT scan after cystectomy (January 2019); B) partial response at CT scan after three cycles of 
chemotherapy (April 2019); C) disease progression at CT scan after six cycles of chemotherapy (July 2019); D) response after radiotherapy and pembrolizumab 
(October 2019). 
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with pembrolizumab at dose of 200 mg every three weeks. A concurrent 
stereotactic radiotherapy treatment (6X FFF photon beams with a total 
dose of 30 Gy in 3 fractions) was performed on breast and subcutaneous 
metastasis of chest wall. 
After stereotactic radiotherapy and 4 cycles of pembrolizumab, 
radiological assessment showed a complete response of subcutaneous 
metastasis of chest wall and a significant reduction of right breast nodule 
(lesion size reduced to Ø 15 × 11 mm). Abdomen lymph nodes were also 
reduced, with non-pathological residual dimensions (short axis <10 
mm) (Fig. 3). 
Discussion 
Before immunotherapy, median OS for patients with advanced UC 
was 9 months and no established therapy was available after failure of 
platinum-based treatment. Development of ICIs has improved both OS 
and quality of life of patients in a second-line therapy setting, with a 
better safety profile compared to traditional chemotherapy.3 In our 
patient pembrolizumab was well tolerated, reporting only low-grade 
hyperthyroidism (grade 2 sec. CTCAE v 5.0) treated and resolved with 
medical therapy. 
The biological rationale for therapeutic efficacy of pembrolizumab 
was suggested by molecular characterization of breast metastatic tissue, 
which resulted in PD-L1 CPS of 30%. Although in KEYNOTE-045 trial 
survival benefit was observed in the total population regardless of PD-L1 
CPS expression, in subgroup analysis the benefit was better in patients 
with PD-L1 CPS of 10% or more.3 
In our clinical case, the exceptional response of metastasis treated 
with radiotherapy could be related to an ICD mechanism that supported 
the action of the immunotherapy. In fact, it is well known that radio-
therapy has direct cytotoxic effects on tumour cells (targeted effects) 
primarily due to production of DNA double-strand breaks. More recent 
evidence has shown that radiotherapy induces phagocytosis of tumour 
cells by dendritic cells (DC) and processing of tumour-derived antigens 
and DC-associated cross-priming of CD8+-CTLs19.4 Therefore, ICD may 
involve the recruitment of host’s immune system, resulting in immune 
memory and advantageous systemic effects, such as the abscopal effect, 
which causes tumour regression in non-irradiated areas.5 
Conclusions 
This reported case of atypical BM of UC confirms that immuno-
therapy represents an excellent therapeutic choice for patients with 
metastatic UC progressed after platinum-based chemotherapy. The as-
sociation of immunotherapy with radiotherapy could have a synergistic 
effect on changes of tumour microenvironment and it could increase 
disease control. 
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